Thus, PARP inhibitors, which currently include olaparib, rucaparib, niraparib and talazoparib, stop the PARP from doing its repair work in cancer cells leading to cancer cells’ death (Golan et al., 2019; Boussios et al., 2022). Here, PARP1 is linked to cancer.